Navigation Links
Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
Date:5/7/2008

this evaluation."

With the addition of SBI-087 -- Trubion's next-generation, fully humanized CD20-directed SMIPTM -- Trubion's pipeline now includes two compounds under development for the treatment of autoimmune and inflammatory diseases. Trubion and Wyeth are leveraging Trubion's SMIPTM technology to create a portfolio of product candidates with customized mechanisms of action in an effort to optimize patient safety, efficacy and convenience.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ewswire/--Reportlinker.comannouncesthatanewmarketr...terMonitoringSystems-AGlobalMarketReview ,, ...ring-Systems---A-Global-Market-Review.html#utm_sou...prnewswire ,, Cardiovascularmonitoringisext...tsneedtobecontinuouslymonitoredduringdiagnosticasw...
(Date:11/23/2009)....23/PRNewswire/--LightSciencesOncology,Inc.(LSO)to...eBoard,Elekta,toanewlycreatedseatonitsboardofdirec...cal-productcompanies,includingElekta,tomarketleade...ditionalstrengthinbusinessdevelopmenttotheboard,"s...saworldleaderincancer-therapybusinessdevelopment.H...
(Date:11/23/2009)...Nov.23/PRNewswire/--Sarnova,Inc.,thenation,sleadin...gencymedicalservices(EMS)andrespiratorymarkets,ann...niormanagementteam.ThenewexecutivesincludeTomDavid...vicepresidentandgeneralcounsel;SteveLacke,executiv...ivevicepresidentofcorporatedevelopment. ,, "Iha...
Breaking Medicine Technology:Reportlinker Adds Holter Monitoring Systems - A Global Market Review 2Reportlinker Adds Holter Monitoring Systems - A Global Market Review 3Reportlinker Adds Holter Monitoring Systems - A Global Market Review 4Reportlinker Adds Holter Monitoring Systems - A Global Market Review 5Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors 2Sarnova Expands Senior Management Team 2Hartfords Camp Courant Gets a Brick Up on Summer Thanks to 24100 000 Grant From The LEGO 28R 29 Childrens Fund 51992 1Hartfords Camp Courant Gets a Brick Up on Summer Thanks to 24100 000 Grant From The LEGO 28R 29 Childrens Fund 51992 2Hartfords Camp Courant Gets a Brick Up on Summer Thanks to 24100 000 Grant From The LEGO 28R 29 Childrens Fund 51992 3Sanford Rose Associates Opens Minneapolis Office 13075 1Sanford Rose Associates Opens Minneapolis Office 13075 2Center for Medicines 26 Healthy Aging 28C 29 and BidRx 28R 29 Partner to Help Consumers Save on Prescription Medications 51986 1Center for Medicines 26 Healthy Aging 28C 29 and BidRx 28R 29 Partner to Help Consumers Save on Prescription Medications 51986 2Center for Medicines 26 Healthy Aging 28C 29 and BidRx 28R 29 Partner to Help Consumers Save on Prescription Medications 51986 3
(Date:11/23/2009)...nifer Heys wants to make her message clear: there ...about contraception. , Heys, research, on HIV-p...children, was read by experts from all over the wo...nference on Family Planning in Kampala, Uganda. ,..., spent six months interviewing 421 people who liv...
(Date:11/23/2009)...tructive Surgery...In Brief is distributed monthly...ent journal news from the American Society of Plas...ghlighted here, or to arrange an interview with a ... at (847) 228-9900 or media@plasticsurgery.org. ,... -- Yes, Plastic Surgeons Have Plastic Surgery Too...
(Date:11/23/2009)...usandsofpeoplewithiPhoneshavealreadydownloadedGluc...ettermanagetheirdiseasethroughabetterunderstanding...getheirbloodsugar.Nowit,sbecomeeveneasierthroughaf...heDiabetesCare,themakeroftheACCU-CHEK®lineofb...neredwithMYLEstoneHealth,thedeveloperofGlucoseBudd...
(Date:11/23/2009)...eportlinker.comannouncesthatanewmarketresearchrepo...portlinker.com/p0165298/Childrens-Food-and-Drinks-...tion-2nd-Edition.html#utm_source=prnewswire&ut...spitethegrowingattentionbeingpaidtotheworld,sagein...pthatcannotbeoverlooked.Childrenagedbetween5and14r...
(Date:11/23/2009)...hwade,M.D.announcesthenewlyenhancedCyberKnifeequip...rofMiami,( www.cyberknifemiami.com ). ,, TheC...ensedoseofradiationthatkillscancercellswithnoinvas...from30minutestoonehour,andisusuallycompletedin1-5t...erintheSoutheasternU.S.,theMiamifacilityhasledthew...
Breaking Medicine News(10 mins):Health News:AIDS research reveals a lack of family-planning programs in Uganda 2Health News:Plastic and Reconstructive Surgery...In Brief 2Health News:Plastic and Reconstructive Surgery...In Brief 3Health News:ACCU-CHEK(R) Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy.com 2Health News:ACCU-CHEK(R) Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy.com 3Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 2Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 3Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 4Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 5Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 6Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 7
...aware of it - they might not be aware of it, but t...g you down. , New research by University of Calga...h says that regardless of their intentions, having...a complex assembly line, said Welsh If you are doi...
...N.C. The standard test for measuring blood sugar ... those on kidney hemodialysis, according to new re...enter. , Wake Forest investigators reported in K...patients and physicians. Hemodialysis, in which bl...
...s available in French . , Montreal, February 20...fight against age-related macular degeneration, or... of people. An international team, led by research...y edition of the medical journal PLoS Medicine, th...
... deficiencies in early pregnancy can cause locomot...earch from the Swedish medical university Karolins... brain development and could affect routine pregna...untreated. However, scientists are unsure about wh...
...0 LCA-Vision Inc. (Nasdaq:,LCAV), a leading provi...LasikPlus brand, announced today that its Board of...ount of $0.18 per share. The dividend will be,paya...r vision correction services,under the LasikPlus b...
...., Feb. 20 When Avaya rolls its,18-wheel Mobile B...IMSS08,next week, onboard will be a broad range of...ping healthcare organizations address critical,com...d services., As healthcare organizations increasi...
Other Medicine News:Health News:Who's slowing you down? 2Health News:Standard test for blood sugar control not accurate in diabetic dialysis patients 2Health News:AMD discovery: New hope for treatment of vision loss 2Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 2Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 3Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 4
Apolipoprotein A-1
Apolipoprotein A-1 (Liquid)
Urea (BUN)
Gamma GT (Modified IFCC)
Medicine Products: